Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
Shipeng He, Junhui Ma, Yuxin Fang, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 6, pp. 1617-1628
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Drugging p53 in cancer: one protein, many targets
Ori Hassin, Moshe Oren
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 2, pp. 127-144
Open Access | Times Cited: 381
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 159
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 137
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 88
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 72
Discovery of E3 Ligase Ligands for Target Protein Degradation
Jaeseok Lee, Young‐Jun Lee, Young Mee Jung, et al.
Molecules (2022) Vol. 27, Iss. 19, pp. 6515-6515
Open Access | Times Cited: 67
Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, et al.
Cancer Discovery (2023) Vol. 13, Iss. 5, pp. 1210-1229
Open Access | Times Cited: 58
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wei Wang, Najah Albadari, Yi Du, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 414-453
Open Access | Times Cited: 28
Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation
Bhaskarjyoti Gogoi, Purvita Chowdhury, Nabajyoti Goswami, et al.
Molecular Diversity (2021) Vol. 25, Iss. 3, pp. 1963-1977
Open Access | Times Cited: 62
Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2
Wenguang Yang, Wenjia Liu, Xiang Li, et al.
Journal of Advanced Research (2022) Vol. 45, pp. 59-71
Open Access | Times Cited: 51
It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy
Che-Pei Kung, Jason D. Weber
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 46
PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Xin Han, Wenyi Wei, Yi Sun
Acta Materia Medica (2022) Vol. 1, Iss. 2
Open Access | Times Cited: 45
Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
Xin Han, Yi Sun
Cell Reports Physical Science (2022) Vol. 3, Iss. 10, pp. 101062-101062
Open Access | Times Cited: 44
Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond
Yue Zhong, Fanglian Chi, Hanyu Wu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114142-114142
Closed Access | Times Cited: 39
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, et al.
The Innovation (2023) Vol. 4, Iss. 3, pp. 100413-100413
Open Access | Times Cited: 33
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy
Ritesh P. Bhole, Payal R. Kute, Rupesh V. Chikhale, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106720-106720
Closed Access | Times Cited: 22
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Youyi Huang, Xiaofang Che, Peter Wang, et al.
Seminars in Cancer Biology (2024) Vol. 101, pp. 44-57
Closed Access | Times Cited: 10
Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation
Donghuan Sun, Jing Zhang, Guoqiang Dong, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 21, pp. 14276-14288
Closed Access | Times Cited: 36
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
Si Chen, Xiang Li, Yinghua Li, et al.
Theranostics (2022) Vol. 12, Iss. 15, pp. 6665-6681
Open Access | Times Cited: 29
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
Jianyu Yan, Tengfei Li, Zhenyuan Miao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8798-8827
Closed Access | Times Cited: 28
Targeted protein degradation in drug development: Recent advances and future challenges
Jian H. Song, Mingzheng Hu, Jun Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115839-115839
Closed Access | Times Cited: 17
An Overview of PROTACs Targeting MDM2 as a Novel Approach for Cancer Therapy
Huiwen Li, Xinhui Cai, Xiaoyu Yang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116506-116506
Closed Access | Times Cited: 6
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation
Ching Lin, Jui‐Ling Hsu, Yu‐Tung Hsu, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2025) Vol. 40, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top